87 results about "Small Nuclear Ribonucleic Acid" patented technology

A method for identifying micro ribonucleic acid (RNA) in the blood serum of a lung cancer patient through Solexa technology belongs to the biological medicine technical field, in particular relating to a Solexa technology for measuring the expression of micro RNA in the blood serum of a lung cancer patient as well as an application of the Solexa technology in clinic diagnosis and therapy such as early diagnosis of lung cancer, curative effect appraisement and drug effect appraisement, etc. The Solexa technology comprises the following steps that: a Solexa sequencing method is used to measure the content of micro RNA in the blood serum of a lung cancer testee; the appraisement of the physiological and / or pathological status of the testee is to carry out lung cancer diagnosis of the testee; and the physiological and / or pathological status of the testee is tested after the testee receives a to-be-tested object. The Solexa sequencing method has the advantages of wide detection pedigree, high sensitivity, low detection cost, convenient material obtaining and easily stored samples, etc.; moreover, the method can be widely used in related operations including lung cancer screening, etc. so as to improve the conditions of low specificity and low sensitivity caused by individual difference which is difficult to be overcome by a single marker; therefore, the method can substantially increase the clinic detection rate of lung cancer, and is an effective way to carry out early diagnosis of lung cancer.

The invention belongs to the technical field of biotechnology, and discloses a miRNA combination used for detecting esophageal squamous cell carcinoma and application thereof. The miRNA combination comprises miR-22, miR-127-3p, miR-148b and miR-223, and the miRNA combination can further comprise one or more of miR-10a, miR-100 and miR-133a. A kit comprises a probe combination of the miRNAs. The miRNA combination and the probe combination thereof provided by the invention can be used for detecting the esophageal squamous cell carcinoma, and can be used as a diagnosis marker for improving the accuracy of detection, improving the insuperable low specificity and low sensitivity, caused by individual difference, of a single marker, and improving a clinical detectable rate remarkably by combining other detection indicators and clinical symptoms of a patient, so the miRNA combination and the probe combination thereof become an effective means for early diagnosis of the esophageal squamous cell carcinoma. Due to the adoption of the miRNA combination, a noninvasive serological test is adopted so as to bring convenience to clinical promotion.

The invention provides the combination of microRNAs used for evaluating the liver cancer condition of a subject and contains microRNAs which exist stably and are detectable in the serum / plasma of the subject. A method for evaluating the liver cancer condition of the subject comprises a step of measuring the microRNAs which exist stably and are detectable in the serum / plasma of the subject. A kit used for evaluating the liver cancer condition of the subject contains a tool for measuring the microRNAs which exist stably and are detectable in the serum / plasma of the subject. A biochip for evaluating the liver cancer condition of the subject contains a component for measuring the microRNAs which exist stably and are detectable in the serum / plasma of the subject. The novel technology can be used in the aspects of the diagnosis and the differential diagnosis, the prognosis of the generation and the recurrence of the disease complication and the therapeutic effect evaluation of liver cancer, the screening and the pharmacological effect evaluation of medicinal active ingredients and the like.

The invention relates to 17 specific micro ribonucleic acids serving as cervical cancer detection markers, existing in human serum / plasma and capable of being detected, and a method, a related kit and a biochip for detecting the markers. The markers can be used for diagnosis and identification of cervical cancer, prediction of occurrence and relapse of disease complications, curative effect evaluation, screening of medicinal active ingredients, medicinal effect evaluation and the like, have the advantages of broad detection spectrum, high sensitivity, low detection cost, convenience for taking materials and the like, and are easy to store samples. The method can be widely used for related operations such as cervical cancer general investigation and the like, improves low specificity and low sensitivity caused by individual difference difficult to be overcome by single marker, remarkably improves the clinical detection rate of the cervical cancer, and becomes an effective means for early diagnosing the cervical cancer.

The invention discloses a detection card for rapidly detecting micro ribonucleic acid (miRNA). The detection card comprises a sample pad, a nanomaterial pad, a nitrocellulose membrane and an absorbent pad, wherein the nitrocellulose membrane is a detection card substrate, a sample injection zone, a blank control zone and a sample detection zone are distributed on the detection card substrate, the sample injection zone is communicated with the sample detection zone, the blank control zone and the sample detection zone are modified with probes having miRNA sequences complementary to to-be-detected miRNA, one ends of the probes are connected with the detection card substrate, and the other ends of the probes carry fluorescent groups. The invention also discloses a preparation method of the detection card. The invention also discloses a kit for rapidly detecting the miRNA associated with lung cancer. The invention also discloses application of the detection card and the detection kit. The detection card has relatively high detection sensitivity on miRNA associated with lung cancer and can simultaneously detect a plurality of miRNAs without PCR, the clinical diagnostic specificity is improved and the detection card meets application requirements of screening, diagnosis of lung cancer, determination of treatment effect and follow-up visit.

The invention belongs to the field of gene engineering, and discloses mitochondrion correlation serum micro ribonucleic acid serving as markers of human obesity occurrence and application thereof. The markers are some miRNA which is mitochondrion correlation miRNA and is selected from hsa-miR-141-3p, hsa-miR-196a-5p, hsa-miR-210-3p, hsa-miR-378a-3p, hsa-miR-484 and hsa-miR-499a-5p. Obesity cases and normal body weight can be well contrasted and separated, and the markers can be used for preparing obesity diagnosing or monitoring kits.